• CONCLUSION: IL-13 in vitro inhibit ARPE-19 cell proliferation and expression in the aqueous may be associated with AMD.
INTRODUCTION
A ge-related macular degeneration (AMD) is one of the most common causes of blindness in elderly individuals in the developed world [1] . AMD is typically categorized into two forms: wet form and dry form. The pathology of neovascular (wet) AMD is related to the process of choroidal neovascularization (CNV), which leads to leak exudates and hemorrhage. The neovascular membrane in the macular region becomes fibrotic and forms a disciform scar in the involutional stage, which causes irreversible damage and explains the severe central visual loss experienced by these patients [2] .
While molecular and cellular mechanisms underlying CNV are complicated and not fully elucidated, local inflammation and angiogenesis, which influence disease development and prognosis, are recognized as key factors in the progression of wet AMD. Current clinical strategies for treating progressive AMD are primarily aimed at inhibiting vascular endothelial growth factor (VEGF), an endothelial cell mitogen shown to be a key mediator of angiogenesis and a vascular permeabilityenhancing factor. Therefore, only 30% to 40% treated patients gain three lines in visual acuity, some patients continues losing visual acuity, even progressing to blindness [3] . The greater fibrotic response after ranibizumab injection during wound healing process may contribute to poor prognosis [4] [5] . Thus, to explore cytokines related to fibrosis may provide potential novel treatments of AMD. Interleukin (IL)-13 plays pathophysiological roles in allergic inflammation and fibrosis formation. In this study, we quantified IL-13 levels in the aqueous humor of patients with AMD to identify its roles in the pathological process of this condition and investigated its relationship with VEGF, tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) [6] . Identification of these cytokines has enabled the exploration of novel therapeutic approaches.
SUBJECTS AND METHODS
The study protocol was approved by the Ethics Committee of the institute and adhered to the guidelines of the Declaration of Helsinki. Informed consent was obtained from all patients and their families before enrollment. and then cultured in 2% FBS with 10 ng/mL IL-13 treatment for 12, 24, and 48h. The total RNA was extracted using RNA extraction kit (Takara, Japan) according to the manufacturer's instructions and was reverse-transcribed using PrimeScript RT reagent Kit (Takara, Japan). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed with SYBR Green RealMasterMix and specific primers for α-SMA (forward, 5′-GGGACATCAAGGAGAAACTGTGT-3′; reverse, 5′-TCTCTGGGCAGCGGAAAC-3′) and ZO-1 (forward, 5′-TTCCAGATAAAGCCCCAGTTAATG-3′; reverse, 5′-GCAGAAGATTGTGATTGAATTTAGGA-3′). GAPDH was used as an endogenous standard to estimate the mRNA levels. The PCR programme was designed as follows: the cDNA was denatured at 95℃ for 30s followed by 40 cycles of 95℃ for 15s, 60℃ for 30s and 72℃ for 30s. Western Blot ARPE-19 cells were seeded in 25-cm² tissue culture flask in amounts of 4×10 5 cells for incubation of 24h and serum-starved overnight and then cultured in 2% FBS with 10 ng/mL IL-13 treatment for 48h. Cells were harvested in 120 μL 1.5× loading buffer. Samples were clarified by centrifugation at 12 000 rpm at 4℃ for 30min. The homogenates, which contained 30 μg of protein, were then separated by SDS-PAGE and transferred into nitrocellulose membrane (Beyotime, Beijing, China). The blots were probed with the following primary antibodies: α-SMA (Abcam Cambridge, UK; 1:500), ZO-1 (Abcam Cambridge, UK; 1:1000), GAPDH (Abcam Cambridge, UK; 1:5000).
Human Aqueous Humor Specimens
Quantification of the Western blot data was performed by measuring the intensity of the hybridization signals using Image J software, and the ratios of α-SMA and ZO-1 to GAPDH were used as the relative expression level of the target protein.
Enzyme Linked Immunosorbent Assay After experimental incubations as mentioned above, cell culture supernatants were collected and centrifuged for 10min at 1000 g (4 ℃ ) to remove cell debris, then stored at -80℃ until use. The amount of secreted cytokines (TNF-α, TGF-β2 and VEGF) were examined using commercial ELISA kits (eBioscience, USA) according to the manufacturer's protocol. The plates were read at 450 nm, and cytokine levels were extrapolated from standard curves and normalized to protein concentrations. Statistical Analysis All data from quantitative assays were expressed as the mean±standard deviation (SD Figure 3A) . Meanwhile, the α-SMA and ZO-1 protein expression also showed the same tendency in Western blot assay (α-SMA: P=0.038; ZO-1: P=0.008) ( Figure 3B ). Figure  4A) . However, the level of TGF-β2 was significantly increased from 34.44±2.92 to 57.61±6.31 pg/mL at 24h (P=0.004) and from 61.26±1.11 to 86.91±3.59 pg/mL at 48h (P<0.001) ( Figure 4B ). While there was no significant difference of VEGF-A level between IL-13 group and control group ( Figure 4C ).
Effects of Cytokines Induced by

DISCUSSION
The advent of treatments focusing on CNV suppression has caused a major shift in the approach to disease therapy and prevention. Along with the development of molecular biology technology and cell biology, investigation into the roles of cytokines in the pathogenesis of CNV has progressed. The advent of intravitreous VEGF inhibitors has revolutionized the management of neovascular AMD [7] . Although these available treatments may limit CNV progression to a certain extent, a portion of CNV patients still experience clinical deterioration. Furthermore, the loss of VEGF neuroprotectivity can be a potential side effect [8] [9] [10] . Therefore, new antiangiogenic therapies for CNV are eagerly awaited. Our results support the previous viewpoints. IL-13, a cytokine mainly produced by type 2 helper T cells and monocytes/macrophages, plays pathophysiological roles in allergic inflammation and fibrosis formation, and more recently has been shown to play a pivotal role in a number of fibrotic diseases including hepatic and pulmonary fibrosis, and nodular sclerosing Hodgkin's disease [11] [12] . In this study, we found that IL-13 of aqueous humor was significantly upregulated during AMD development, suggesting that IL-13 could have potent effects on the pathological process of this disease. During chronic inflammation, IL-13 is induced concomitantly with activation of its downstream signaling via an IL-13 receptor, IL-13 Rα2 [13] . Concentrations of IL-13 increased in vitro could inhibit ARPE-19 cell proliferation in our study. The degeneration and decrease in cell viability of RPE cell are mostly contributed to process of AMD [14] [15] . We also found that IL-13 (10 ng/mL) can promote EMT in ARPE-19 cells. Greater fibrotic responses after IL-13 may result from an imbalance in the complex interactions between angiogenesis and pro-fibrotic signaling pathway. In the development of AMD, the formation of neovascular membrane fibrosis leads to the development of disciform scars, which indicate irreversible damage [16] . Meanwhile, there is no effective therapy for the associated symptoms once central vision decreases because of metamorphosis and scotoma caused by the scarring. IL-13 is an indispensable mediator of fibrosis [17] . Recently, it was discovered that TGF-β, which contribute to the pathogenesis of subretinal fibrogenesis and angiogenesis, promotes the differentiation of fibroblasts into myofibroblasts, and can be regulated by IL-13 [18] . TGF-β is of primary importance in the development of AMD as it is a strong inducer of extracellular matrix synthesis and accumulation [19] . Moreover, TGF-β can induce the transformation of RPE cells into fibroblast-like cells in vitro [20] . TGF-β2, as a number of TGF-β family, is the main isoform of TGF-β in the eye and it is produced locally [21] [22] [23] .
In this study, we found IL-13 could significantly upregulate the concentrations of TGF-β2 in ARPE-19 cells. Similar foundings have been shown that IL-13 induces lung fibrosis by selectively stimulating TGF-β [24] [25] . Blockage of TGF and IL-13 receptors prevents the progression of fibrosis [26] [27] [28] . In this study, we also found IL-13 could inhibit TNF-α. TNF-α, as a potent proinflammatory cytokine implicated in tissue damages, mediates RPE cell dysfunction and plays an important role in the pathology of AMD [29] [30] . TNF-α increases the expression of VEGF and promotes monocyte-RPE adhesion [31] [32] .
Accumulating evidence supports the theory that other factors, such as IL-13, also play a crucial role in the development of AMD [1, 33] . This study suggested that the possible mechanism of IL-13 in AMD: to promote the transformation from chronic inflammation to fibrogenesis by decreasing TNF-α and upregulating TGF-β. In addition, reports on the effects of IL-13 on angiogenesis have been controversial. Some studies suggest that IL-13 inhibits tube formation and endotheliocyte migration [34] . IL-13 also reportedly suppresses the expression of VEGF and attenuates vascular tube formation via the JAK2-STAT6 pathway [35] . Haas et al [36] found that IL-13 an in vivo antiangiogenic factor and provide a rationale for its use in rheumatoid arthritis to control pathologic neovascularization. Nevertheless, our study in vitro showed that IL-13 couldn't affect the accumulation of VEGF in ARPE-19 cells. The present study reveals the relationship of IL-13 with AMD. Therapys targeting VEGF alone already prove inadequate. Focusing on IL-13 and other factors involved in disciform scarring, which prolongs the time for effective treatment, can bring about a major shift in the approach to disease treatment and prevention. This potential bio-target may also improve prognosis assistant with anti-VEGF treatments. However, this study did not investigate the relationship between the size or extent of disciform scarring and IL-13 levels. This needs to be clarified in further research. In summary, our study showed that concentrations of IL-13 increased in aqueous humor of patients with AMD and in vitro inhibited ARPE-19 cell proliferation, suggesting that IL-13 may play important roles in the pathogenesis of neovascular Email:ijopress@163.com AMD. Furthermore, the possible mechanism of IL-13 in the pathogenesis of AMD was investigated that IL-13 may promote the transformation from chronic inflammation to fibrogenesis by decreasing RPE cell viability and regulating concentrations of related cytokines. These findings may provide evidence to support the development of future AMD therapies.
